Lv3
206 积分 2021-05-27 加入
Trends in the landscape of clinical trials of innovative drugs in China since 2015
6天前
已完结
Trends and challenges in bispecific antibody production
3个月前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
3个月前
已完结
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
3个月前
已完结
Active biointegrated living electronics for managing inflammation
3个月前
已完结
Productivity and quality improvement for a symmetric bispecific antibody through the application of intensified perfusion cell culture
3个月前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
9个月前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
10个月前
已完结
Averting inflammation by targeting the cytokine environment
10个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
10个月前
已完结
皖公网安备34019202002308
